Quantum BioPharma Ltd. (NASDAQ:QNTM) shares rose 10% in premarket Monday after the company announced patient enrollment in its collaborative study with Massachusetts General Hospital reached the halfway mark with encouraging preliminary imaging results.
The study aims to validate a PET imaging technique that assesses demyelinated neurons and tracks demyelination in multiple sclerosis patients. It uses the PET tracer [¹⁸F]3F4AP.
The first cohort was successfully imaged using advanced PET/MR and total-body PET platforms. Preliminary analyses show strong signal in acute MS lesions and potential sensitivity to gray matter lesions.
"We are excited to reach this important midpoint and encouraged by the strength of the preliminary imaging data," said Dr. Andrzej Chruscinski, VP of Scientific and Clinical Affairs at Quantum BioPharma.
This imaging approach could enable more precise measurement of therapy impact on myelin preservation, potentially enhancing evaluation of treatments including Quantum's investigational candidate, Lucid-MS.
Lucid-MS is designed to inhibit demyelination by targeting PAD2 enzyme. The company submitted an IND for Phase 2 to the FDA in March 2026.
Prior Phase 1 trials showed Lucid-MS had a favorable safety profile.
